Asciminib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 310 publications
Response by Stepanian and Jaffe to Letters Regarding Article, "Ponatinib, but Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke".
Journal: Circulation
Published: April 06, 2026
Tyrosine kinase inhibitors, chronic myeloid leukemia, and pregnancy: pharmacotherapeutic challenges and recommendations.
Journal: Expert opinion on pharmacotherapy
Published: March 24, 2026
Painful fissured plaques on the palms and soles in a patient with chronic myeloid leukemia.
Journal: JAAD case reports
Published: March 09, 2026
Key points in selecting first-line therapy for chronic myeloid leukemia
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: March 04, 2026
Key points in second-line therapy for chronic myeloid leukemia
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: March 04, 2026
From Molecular Silence to Lymphoid Blast Phase: Diagnostic and Therapeutic Challenges in a Young Female Patient With Chronic Myeloid Leukemia.
Journal: Cureus
Published: February 18, 2026
Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design.
Journal: Circulation
Published: February 12, 2026
Structural and In silico safety evaluation of asciminib degradation products with a validated stability indicating HPLC method for genotoxic impurity determination.
Journal: Scientific reports
Published: January 31, 2026
Last Updated: 04/28/2026